Hemoglobinuria

(redirected from paroxysmal nocturnal hemoglobinuria)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to paroxysmal nocturnal hemoglobinuria: Paroxysmal cold hemoglobinuria

hemoglobinuria

[‚hē·mə‚glō·bə′nu̇r·ē·ə]
(medicine)
A pathological condition in which the urine contains hemoglobin.

Hemoglobinuria

 

the presence of hemoglobin in urine. It usually is a result of the intravascular decomposition of red blood cells following the transfusion of incompatible blood, the effect of some chemical and biological poisons and drugs that cannot be tolerated or of any of several causative agents of infections, extensive injuries, and so on.

References in periodicals archive ?
Reversible renal failure in paroxysmal nocturnal hemoglobinuria.
The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria.
The data were highlighted in an oral presentation titled, "High Incidence of Progression to Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy.
Alexion's two lead product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs, including two Phase III trials of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a Phase III trial of pexelizumab in coronary artery bypass graft (CABG) surgery patients undergoing cardiopulmonary bypass (CPB), and a Phase III trial of pexelizumab in acute myocardial infarction (AMI) patients.
Soliris is approved in the US, European Union, Japan and other countries as the first and only treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder, characterized by complement-mediated hemolysis (destruction of red blood cells).
According to the announcement, the Company attributes this increase in revenue to steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment across the Company's 50-country global platform.
Patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) were found to be six times more likely than the general public to have chronic kidney disease (CKD), as shown in an ongoing open-label clinical study of patients with PNH.
Alexion remains on track to complete treatment in the TRIUMPH Phase III pivotal trial with its lead drug candidate eculizumab in the orphan blood disorder Paroxysmal Nocturnal Hemoglobinuria ("PNH").
Nasdaq: ALXN) today announced that researchers will present data from clinical studies of Soliris([R]) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders, at the 54th Annual Meeting of the American Society of Hematology (ASH).
The first indication is paroxysmal nocturnal hemoglobinuria (PNH), a rare disease of the bone marrow.

Full browser ?